Schedule 13G ownership disclosure

Monte Rosa Therapeutics Inc

Common Stock · CUSIP: 61225M102

Event date: 2025-09-30

Filing-level shares
2,988,953
Percent of class
4.83%
  • The Vanguard Group

    Shares: 2,988,953 · Class: 4.83%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000102909-25-000255
Form type
SCHEDULE 13G/A
Filer
Monte Rosa Therapeutics, Inc.
CIK
CIK 1826457
Filed
Oct 31, 2025
Reporting period
Sep 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub